Knight Therapeutics Closes US$38.5 Million Loan with IFC

MONTREAL, Dec. 23, 2022  (GLOBE NEWSWIRE) --  Knight Therapeutics Inc.,  (TSX:
GUD)   (“Knight”)   a    pan-American   (ex-USA)   specialty    pharmaceutical
company, today announced  that  it has  closed  a five-year,  US$38.5  million
secured  loan  denominated  in  select  Latin  American  currencies  with  the
International Finance Corporation (“IFC”),  a member of  the World Bank  Group
focused on the private sector in emerging markets.

The IFC loan is  denominated in Brazilian Real,  Colombian Peso, Chilean  Peso
and Mexican Peso, with the  Brazilian Real tranche representing  approximately
50% of the loan and  the balance split among the  rest of the currencies.  The
IFC loan  maturity date  is on  October 15,  2027, with  principal  repayments
starting on October 15,  2023. Furthermore, the  loan has customary  covenants
and is secured by select assets of  Knight including a cash collateral of  35%
of the principal outstanding.

“We  are  pleased  with  the  financial  flexibility  provided  through   this
partnership with IFC,” said Arvind Utchanah, Chief Financial Officer of Knight
Therapeutics Inc. “The  loan, coupled  with Knight’s  existing cash  position,
further strengthens our balance sheet while providing a natural hedge  against
future currency depreciation in the key markets in which we operate.”

About Knight Therapeutics Inc.

Knight Therapeutics Inc.,  headquartered in Montreal,  Canada, is a  specialty
pharmaceutical   company   focused   on   acquiring   or   in-licensing    and
commercializing pharmaceutical products for Canada and Latin America. Knight's
Latin American subsidiaries operate under United Medical, Biotoscana Farma and
Laboratorio LKM.  Knight Therapeutics  Inc.'s shares  trade on  TSX under  the
symbol GUD. For more information about Knight Therapeutics Inc., please  visit
the company's web site at www.gud-knight.com or www.sedar.com.

Forward-Looking Statement

This document contains forward-looking statements for Knight Therapeutics Inc.
and its  subsidiaries.  These  forward-looking statements,  by  their  nature,
necessarily involve risks and uncertainties that could cause actual results to
differ materially from those  contemplated by the forward-looking  statements.
Knight  Therapeutics   Inc.  considers   the   assumptions  on   which   these
forward-looking statements are based  to be reasonable at  the time they  were
prepared but  cautions  the reader  that  these assumptions  regarding  future
events, many of which are beyond  the control of Knight Therapeutics Inc.  and
its subsidiaries, may  ultimately prove  to be incorrect.  Factors and  risks,
which  could  cause   actual  results  to   differ  materially  from   current
expectations are discussed in Knight Therapeutics Inc.'s Annual Report and  in
Knight Therapeutics Inc.'s Annual Information Form for the year ended December
31, 2021 as  filed on  www.sedar.com. Knight Therapeutics  Inc. disclaims  any
intention or obligation  to update  or revise  any forward-looking  statements
whether because of  new information or  future events, except  as required  by
law.

Investor Contact:                      
Knight Therapeutics Inc.               
Samira Sakhia                         Arvind Utchanah
President & Chief Executive Officer   Chief Financial Officer
T: 514.484.4483                       T. +598.2626.2344
F: 514.481.4116                        
Email: info@knighttx.com              Email: info@knighttx.com
Website: www.gud-knight.com           Website: www.gud-knight.com